SCHEMBL4482965

SCHEMBL4482965

O=C(CCc1ccccc1)Nc1onc(-c2cccc3ccccc23)c1-c1ccncc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.68
LMNA P02545 2/20 0.47
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NPY5R Q15761 2/20 0.40
KDM6B O15054 1/20 0.40
KDM4D Q6B0I6 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
EGLN3 Q9H6Z9 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
KCNJ11 Q14654 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335598 0.90 MAPK14 (0.67) MAPK14LMNANPC1RAB9ASMN1; SMN2
SCHEMBL4334980 0.86 MAPK14 (0.88) MAPK14LMNASMN1; SMN2KDM4EMAPT
SCHEMBL4336205 0.86 MAPK14 (0.70) MAPK14LMNAKDM4EALDH1A1HPGD
SCHEMBL4331928 0.85 MAPK14 (0.67) MAPK14LMNASMN1; SMN2KDM4EALDH1A1
SCHEMBL4333453 0.85 MAPK14 (0.72) MAPK14LMNANPC1RAB9ASMN1; SMN2
SCHEMBL27765838 0.84 MAPK14 (0.68) MAPK14LMNAMAPTNPY5RKDM6B
SCHEMBL4343869 0.84 MAPK14 (0.70) MAPK14LMNANPC1HSP90AA1
SCHEMBL4330108 0.83 MAPK14 (0.69) MAPK14LMNANPC1RAB9ASMN1; SMN2
SCHEMBL4333469 0.83 MAPK14 (0.86) MAPK14LMNANPY5RKDM6BKDM4D
SCHEMBL4336989 0.83 MAPK14 (0.75) MAPK14LMNANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
CN-101472921-A Pyridylisoxazole derivative ASKA PHARM CO LTD (JP) 2009-07-01 CN disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885LMNA 4792/4885NPC1 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.